Teva's organ rejection drugs get EMEA recommendation

12/16/2007 | Globes (Israel)

The European Medicines Agency recommended approval of two generic organ rejection drugs manufactured by Teva Pharmaceutical Industries Ltd. The two medicines, which are generic versions of Roche Holding's CellCept, are indicated for the prevention of acute transplant rejection in kidney, heart or liver transplant patients.

View Full Article in:

Globes (Israel)

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Catheter Engineer Manager
ASAHI INTECC, Orange County CA R&D Center
Santa Ana, CA
Neurovascular Intervention Product Sales Rep, North East
ASAHI INTECC
Multiple Locations, SL_Multiple Locations
Senior Manager, Compliance
Stryker
Fremont, CA
Director, Office of Device Evaluation
FDA, Center for Devices and Radiological Health
Silver Spring, MD
Director, Office of Compliance
FDA, Center for Devices and Radiological Health
Silver Spring, MD